(Reuters) – An experimental new breast cancer drug made from sea sponges helped in a range of cancers, from breast cancer to sarcoma, researchers report.
Three studies show the drug, Eisai’s eribulin, was effective and tolerated in patients with breast cancer, colon cancer and urinary cancer, according to brief data released on Thursday by the American Society of Clinical Oncology. Sarcomas are cancers that grow from muscle or bone.
A fourth study of patients with advanced breast cancer will be detailed in a “late-breaker” session at ASCO’s annual meeting in June.
The drug is not yet approved, but Eisai has filed with relevant agencies in Japan, the United States and Europe.
The drug works on the same principle, but with a slightly different mechanism as older cancer drugs such as the taxanes and is infused intravenously.
Only a few details are available in the abstracts of the research published ahead of the meeting. Read more…
